| General Information | |
|---|---|
| ZINC ID | ZINC000028528650 |
| Molecular Weight (Da) | 498 |
| SMILES | C[C@H](NS(C)(=O)=O)c1ccc(S(=O)(=O)c2ccc(Cl)cc2Cc2ccc(Cl)cc2)cc1 |
| Molecular Formula | C22Cl2N1O4S2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 125.245 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 31 |
| LogP | 5.532 |
| Activity (Ki) in nM | 162.181 |
| Polar Surface Area (PSA) | 97.07 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | + |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.04560935 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.18 |
| Ilogp | 3.06 |
| Xlogp3 | 5.2 |
| Wlogp | 6.86 |
| Mlogp | 4.34 |
| Silicos-it log p | 4.72 |
| Consensus log p | 4.84 |
| Esol log s | -6.17 |
| Esol solubility (mg/ml) | 3.34E-04 |
| Esol solubility (mol/l) | 6.70E-07 |
| Esol class | Poorly sol |
| Ali log s | -6.99 |
| Ali solubility (mg/ml) | 5.15E-05 |
| Ali solubility (mol/l) | 1.03E-07 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.62 |
| Silicos-it solubility (mg/ml) | 1.21E-07 |
| Silicos-it solubility (mol/l) | 2.42E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.65 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.8 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.954 |
| Logd | 3.109 |
| Logp | 5.199 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | 2.04E-05 |
| Ppb | 0.989 |
| Vdss | 0.417 |
| Fu | 0.0126 |
| Cyp1a2-inh | 0.378 |
| Cyp1a2-sub | 0.667 |
| Cyp2c19-inh | 0.928 |
| Cyp2c19-sub | 0.44 |
| Cl | 2.277 |
| T12 | 0.018 |
| H-ht | 0.917 |
| Dili | 0.995 |
| Roa | 0.083 |
| Fdamdd | 0.989 |
| Skinsen | 0.031 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.009 |
| Bcf | 0.724 |
| Igc50 | 4.744 |
| Lc50 | 4.653 |
| Lc50dm | 4.653 |
| Nr-ar | 0.001 |
| Nr-ar-lbd | 0.008 |
| Nr-ahr | 0.16 |
| Nr-aromatase | 0.037 |
| Nr-er | 0.118 |
| Nr-er-lbd | 0.004 |
| Nr-ppar-gamma | 0.049 |
| Sr-are | 0.57 |
| Sr-atad5 | 0.003 |
| Sr-hse | 0.004 |
| Sr-mmp | 0.901 |
| Sr-p53 | 0.005 |
| Vol | 453.268 |
| Dense | 1.097 |
| Flex | 22 |
| Nstereo | 0.318 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 1 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 1 |
| Qed | 1 |
| Synth | 0.496 |
| Fsp3 | 2.733 |
| Mce-18 | 0.182 |
| Natural product-likeness | 46 |
| Alarm nmr | -1.213 |
| Bms | 2 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Accepted |
| Goldentriangle | Rejected |